|1.||Hilberg, Frank: 4 articles (12/2015 - 06/2008)|
|2.||Kaiser, Rolf: 4 articles (02/2015 - 01/2010)|
|3.||Stopfer, Peter: 4 articles (06/2011 - 10/2009)|
|4.||Kaneda, Hiroyasu: 3 articles (02/2015 - 10/2010)|
|5.||Temple, Graham: 3 articles (02/2014 - 10/2011)|
|6.||Stopfer, P: 3 articles (08/2012 - 02/2010)|
|7.||Kaiser, R: 3 articles (08/2012 - 06/2011)|
|8.||Terashima, Masaaki: 2 articles (02/2015 - 10/2010)|
|9.||Nakagawa, Kazuhiko: 2 articles (02/2015 - 10/2010)|
|10.||Sarashina, Akiko: 2 articles (02/2015 - 10/2010)|
|1.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
06/01/2012 - "The preliminary clinical efficacy of BIBF 1120 is discussed in the context of the most relevant clinical data in several malignancies including non-small cell lung cancer."
08/01/2013 - "BIBF 1120/ nintedanib : a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer."
06/01/2011 - "To assess the efficacy, safety, tolerability and pharmacokinetics of BIBF 1120 in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC). "
06/01/2011 - "A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer."
01/01/2011 - "New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond."
06/01/2010 - "Expert opinion on the promising results obtained in Phase I studies demonstrating that BIBF 1120 is well tolerated in patients with advanced solid tumors will be provided. "
01/01/2010 - "Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors."
09/01/2012 - "[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects]."
02/01/2011 - "Our results suggest that BIBF 1120 is capable of overcoming ABCB1-mediated drug resistance by inhibiting ABCB1 function, which may have clinical significance for BIBF 1120 combinational treatment of certain resistant cancers."
10/01/2010 - "Patients with advanced refractory solid tumors were treated with BIBF 1120 at oral doses of 150 to 250 mg twice daily. "
|3.||Ovarian Neoplasms (Ovarian Cancer)
05/01/2010 - "At the time of publication, intedanib had reached phase III trials for the treatment of NSCLC and ovarian cancer."
10/01/2011 - "Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer."
09/08/2015 - "Here, we designed small-scale siRNA screens targeting these six mesenchymal signature genes (CD99L2, EMP3, ITGA5, SYDE1, VIM, ZEB1) to explore their functional relevance and their roles during EMT reversal by nintedanib (BIBF1120) in a mesenchymal-like SKOV3 ovarian cancer cell line. "
04/01/2011 - "Selective inhibitors of the VEGF pathway (e.g., bevacizumab and VEGF Trap) as well as VEGF/PDGF pathway inhibitors (e.g., sorafenib and sunitinib) and VEGF/PDGF/FGF pathway inhibitors (e.g., cediranib, pazopanib, and BIBF 1120) have shown single-agent activity in women with ovarian cancer in phase II trials. "
10/01/2013 - "The antiangiogenic monoclonal antibody bevacizumab has demonstrated a progression-free survival benefit in combination with first-line paclitaxel/carboplatin and continued as maintenance therapy, and phase II data suggest therapeutic potential for several multitargeted tyrosine kinase inhibitors in ovarian cancer, with phase III results forthcoming for BIBF 1120, cediranib, and pazopanib. "
|4.||Idiopathic Pulmonary Fibrosis
09/22/2011 - "In patients with idiopathic pulmonary fibrosis, BIBF 1120 at a dose of 150 mg twice daily, as compared with placebo, was associated with a trend toward a reduction in the decline in lung function, with fewer acute exacerbations and preserved quality of life. "
09/22/2011 - "In a 12-month, phase 2 trial, we assessed the efficacy and safety of four different oral doses of the tyrosine kinase inhibitor BIBF 1120 as compared with placebo in patients with idiopathic pulmonary fibrosis. "
05/01/2014 - "The tyrosine kinase inhibitor nintedanib (BIBF 1120) is in clinical development for the treatment of idiopathic pulmonary fibrosis. "
01/01/2012 - "BIBF 1120 is a potent triple blocker of the receptors of these growth factors which is currently evaluated as a potential therapy in the idiopathic pulmonary fibrosis. "
05/01/2010 - "Boehringer Ingelheim Corp is developing intedanib (BIBF-1120), a triple kinase inhibitor blocking VEGFR, PDGFR and FGFR for the treatment of several malignancies and idiopathic pulmonary fibrosis. "
|5.||Colorectal Neoplasms (Colorectal Cancer)
06/01/2011 - "Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer."
11/01/2014 - "What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?"
06/01/2011 - "The feasibility of an alternating regimen of BIBF 1120, a potent, oral, triple angiokinase inhibitor, and afatinib (BIBW 2992), a potent ErbB family blocker, was explored in patients with advanced pretreated colorectal cancer (CRC). "
|4.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|5.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|7.||Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)
|8.||sorafenib (BAY 43-9006)
|10.||4- ((4- Fluoro- 2- methyl- 1H- indol- 5- yl)oxy)- 6- methoxy- 7- (3- (pyrrolidin- 1- yl)propoxy)quinazoline (AZD2171)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)